(Q54388747)

English

Chromogranin A staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

Chromogranin A staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

adaptive radiation therapy

0 references

author name string

Daniel J Krauss

1

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

Mitual Amin

2

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

Brandon Stone

3

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

Hong Ye

4

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

Sylvia Hayek

5

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

Matthew Cotant

6

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

Jason Hafron

7

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

Donald S Brabbins

8

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

publication date

30 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

74

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

5

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

520-527

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

Unusual and underappreciated: small cell carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

Androgen receptor alterations in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

Neuroendocrine cells in tumour growth of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

The role of androgens and the androgen receptor in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22771

21 January 2018

Identifiers

10.1002/PROS.22771

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24375481

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54388747&oldid=906827478"